+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vascepa"

From
Disease Analysis: Dyslipidemia - Product Thumbnail Image

Disease Analysis: Dyslipidemia

  • Report
  • November 2020
  • 101 Pages
  • Global
Vascepa - Product Thumbnail Image

Vascepa

  • Report
  • June 2018
  • 11 Pages
  • Global
From
Lovaza - Product Thumbnail Image

Lovaza

  • Report
  • June 2018
  • 11 Pages
  • Global
From
Epanova - Product Thumbnail Image

Epanova

  • Report
  • June 2018
  • 12 Pages
  • Global
From
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Vascepa is a prescription drug used to reduce triglyceride levels in adults with severe hypertriglyceridemia. It is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is the first and only FDA-approved prescription omega-3 fatty acid for this indication. Vascepa is part of a class of cardiovascular drugs known as lipid-lowering agents, which are used to reduce the risk of cardiovascular disease. These drugs work by reducing the amount of cholesterol and triglycerides in the blood. Vascepa is also used to reduce the risk of cardiovascular events, such as heart attack and stroke, in adults with elevated triglyceride levels. The Vascepa market is highly competitive, with several major pharmaceutical companies offering similar products. These include Amarin Corporation, AstraZeneca, GlaxoSmithKline, Merck & Co., and Pfizer. Show Less Read more